Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Current Opinions and Recommendations

16

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) traded with the volume of 1.2 Million in the previous trading session. The Stock opened its session at $0 and closed at $9.22 by showing increase of 5.49 percent. Progenics Pharmaceuticals, Inc. has 1 year price target of $10.8. The stock gained a consensus recommendation of 1 on Zacks Investment Research where the scale runs from 1 to 5, 1 representing Strong buy and 5 showing Strong Sell.  The company reported its last quarter on Sep 16.

On Sep 16 Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) reported its EPS in the last quarter as $0.52/Share lagging the analyst estimate of $0.55/Share by the difference of $-0.03. This showed the surprise of -5.5% in the last quarter earnings. For the Current Quarter, 1 analysts are projecting the mean EPS to be $-0.13/share. According to their observations and findings, the stock could provide a high EPS of $-0.13/share and a Low EPS of $-0.13/share.

The 5 analysts offering 12-month price forecasts for Progenics Pharmaceuticals Inc have a median target of 11.00, with a high estimate of 12.00 and a low estimate of 9.00. The median estimate represents a +19.31% increase from the last price of 9.22. (CNN MONEY)

Many Analysts provided their foresight on Revenue Estimates of Progenics Pharmaceuticals, Inc. where they believe that the company has the potential to earn average revenue of $4.65 Million for the current quarter. According to their predictions High & Low revenue estimates are 6.61 Million and 3.4 Million respectively.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) topped its 52-week high price of $9.78 on Dec 27, 2016 and 52-Week Low Price of $3.61 on Feb 9, 2016. The Stock currently has the market capitalization of $645.52 Million, P/E (price to earnings ttm) of 59.1 and Weekly volatility of 4.52% and monthly volatility of 4.92% respectively.

Progenics Pharmaceuticals, Inc. Gross Margin percentage stands at 0% while its Operating Margin for trailing twelve month is 15.2 percent and Profit margin (ttm) is 15.5 Percent. The stock is currently moving above its 20-Day Simple Moving Average of 15.63% with the 50-Day Simple Moving Average of 15.63 percent. Currently, the company has SMA200 (200-day simple moving average) of 50.87 Percent. The Stock has YTD (year to date) performance of 6.71 percent.

Many research firms have provided their ratings on Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) where Aegis Capital provided Buy rating on the stock on 27-Oct-16. Other firms include Jefferies giving Buy rating on 23-Oct-15.

The latest Insider trade was made on 10 Jun 2015 where Israel (Robert J) Officer did a transaction type “Buy” in which 2000 shares were traded at a price of $5.33. Another insider trade includes Officer Israel (Robert J) who also initiated a transaction in which 2000 shares were traded on 10 Jun 2015 as “Sell”.

Company Profile:

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics’ first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics’ first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc.